TKL Research agrees to sell clinical trials division

Published: 1-Dec-2016
Regulatory Pharmaceutical

TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS.


Upon closing, TKL’s CTD will become part of Novella Clinical, a Quintiles company.

Moving forward, TKL Research will retain its Research Clinics Division (RCD) as TKL Research, Inc., which operates full-service inpatient and outpatient Phase I facilities in northern New Jersey.

 

The transaction, which is subject to standard and customary closing conditions, is expected to close in the fourth quarter of 2016.

 

“It’s exciting to see CTD take this next step in its strategic growth plan,” said Jon C. Anderson, Ph.D., President and CEO of TKL Research. “With this deal, we will continue our focus on providing our inpatient and outpatient Phase I services. We look forward to the future of TKL’s Research Clinics Division as we begin to operate independently as TKL Research, Inc.”

 

Serving as a full-service, global, dermatology CRO since 1995, TKL is headquartered in Rochelle Park, New Jersey and has offices in Fairlawn, New Jersey.

See more

You may also like

Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

Read more
The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Broughton receives flexible scope ISO 17025 accreditation New certification allows accreditation without prior approval
  3. Licensing and supply agreement for voretigene neparvovec outside the US Spark Therapeutics announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialise investigational voretigene neparvovec outside the US, while Spark Therapeutics will continue to exclusively commercialise Luxturna (voretigene neparvovec-ryzl) in the US
  4. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  5. Using ddPCR to accurately quantify AAV viral titre and integrity Gene therapy is primed to become the next major development in medicine and bring relief to patients living with diseases ranging from haemophilia to Alzheimer’s disease, write Mark White, Associate Director of Biopharma Product Marketing, and Marwan Alsarraj, Biopharma Segment Manager, Bio-Rad

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

Marchesini Group at Achema 2024: celebrating 50 years of innovation

At G3, Hall 3.1, the Marchesini Group will exhibit pharmaceutical manufacturing machines, packaging solutions and digital tools to enhance manufacturing processes
Manufacturing

US court lifts modified consent decree on Xellia’s Cleveland facility

The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Subscribe now